BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
2.750
-0.150 (-5.17%)
Feb 24, 2026, 4:00 PM EST - Market closed
BioLineRx Market Cap
BioLineRx has a market cap or net worth of $11.78 million as of February 24, 2026. Its market cap has decreased by -21.40% in one year.
Market Cap
11.78M
Enterprise Value
-2.98M
1-Year Change
-21.40%
Ranking
Category
Stock Price
$2.75
Market Cap Chart
Since July 27, 2009, BioLineRx's market cap has decreased from $33.80M to $11.78M, a decrease of -65.15%. That is a compound annual growth rate of -6.15%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 24, 2026 | 11.78M | -10.09% |
| Dec 31, 2025 | 13.10M | -44.21% |
| Dec 31, 2024 | 23.49M | -79.62% |
| Dec 31, 2023 | 115.26M | 305.33% |
| Dec 29, 2022 | 28.44M | -71.41% |
| Dec 30, 2021 | 99.46M | 66.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Cocrystal Pharma | 13.90M |
| Lunai Bioworks | 13.19M |
| Traws Pharma | 12.87M |
| BioAtla | 12.65M |
| NewcelX | 12.31M |
| Longeveron | 12.27M |
| GT Biopharma | 12.26M |
| CytoMed Therapeutics | 12.12M |